GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)

First Posted Date: 2016-02-23

Last Posted Date: 2019-01-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 112

Registration Number: NCT02688387

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo
Drug: GSK3196165

First Posted Date: 2016-02-17

Last Posted Date: 2021-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT02683785

Locations: 🇬🇧
GSK Investigational Site, York, United Kingdom

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Lyophilized albiglutide DCC pen injector matching placebo
Drug: Lyophilized albiglutide DCC pen injector
Drug: Albiglutide liquid auto-injector
Drug: Albiglutide liquid auto-injector matching placebo

First Posted Date: 2016-02-17

Last Posted Date: 2019-07-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 308

Registration Number: NCT02683746

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

Phase 3

Withdrawn

Conditions: Infections, Respiratory Tract

Interventions: Drug: Paracetamol, phenylephrine HCl, and vitamin C

First Posted Date: 2016-02-09

Last Posted Date: 2018-03-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02678234

A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

Phase 2

Completed

Conditions: Shigella Sonnei Infection

Interventions: Biological: GVGH S. sonnei (1790GAHB) vaccine 25 μg
Biological: Menveo
Biological: GVGH S. sonnei (1790GAHB) vaccine 100 μg
Biological: Boostrix